Investigational drug · Phase 2
AMXI-5001
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Advanced Malignant Neoplasm, Breast Cancer, Ovarian Cancer.
Phase 2Last checked: Nov 20, 2026Latest source record: May 1, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "AMXI-5001"
First trial start
2020
Aug 12, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AMXI-5001", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Malignant Neoplasm
- Breast Cancer
- Ovarian Cancer
- Homologous Recombination Deficiency
- Prostate Cancer
- Pancreatic Cancer
Approved drugs for the same conditions: Breast cancer · Prostate cancer · Ovarian cancer · Pancreatic cancer · Oncology · Rare and genetic disease · Kidney and urology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "AMXI-5001" as an intervention, largest first.
AtlasMedx, IncorporatedIndustry
NCT04503265 · 122 participants (planned) · Start Aug 12, 2020 · Primary completion Aug 2026
Drug: AMXI-5001:Dose Escalation Phase I; AMXI-5001:Dose Expansion Phase II · For: Advanced Malignant Neoplasm; Breast Cancer; Ovarian Cancer and 3 more
Sites: Los Angeles, California; Baltimore, Maryland; Nashville, Tennessee · 4 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Novel dual action PARP and microtubule polymerization inhibitor AMXI-5001 powerfully inhibits growth of esophageal carcinoma both alone and in combination with radiotherapy.
Brand NR, Yang YW, Ding V, et al. · Am J Cancer Res 2024
- AMXI-5001, a novel dual parp1/2 and microtubule polymerization inhibitor for the treatment of human cancers.
Lemjabbar-Alaoui H, Peto CJ, Yang YW, et al. · Am J Cancer Res 2020
Also in development for Advanced Malignant Neoplasm
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.